NCT01711970View on ClinicalTrials.gov

A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 3, 2017

Study Completion Date

May 3, 2017

Conditions
Platinum Resistant Ovarian Cancer
Interventions
DRUG

Paclitaxel

Trial Locations (1)

Unknown

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Vascular Biogenics Ltd. operating as VBL Therapeutics

INDUSTRY

NCT01711970 - A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | Biotech Hunter | Biotech Hunter